Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 24 , ISSUE 3 ( March, 2020 ) > List of Articles

Original Article

Mucormycosis in a Tertiary Care Center in South India: A 4-Year Experience

Poorna Priya, T Rajendran, VG Geni

Keywords : Amphotericin B, Mucorales, Surgical debridement

Citation Information : Priya P, Rajendran T, Geni V. Mucormycosis in a Tertiary Care Center in South India: A 4-Year Experience. Indian J Crit Care Med 2020; 24 (3):168-171.

DOI: 10.5005/jp-journals-10071-23387

License: CC BY-NC 4.0

Published Online: 25-06-2011

Copyright Statement:  Copyright © 2020; The Author(s).


Background: Mucormycosis is an emerging fungal infection in both developed and developing countries with different target population. Unusual isolates and unusual clinical presentations have been reported from India in recent times. Objectives: The present study was done to know the epidemiology, risk factors, diagnostic modalities, and treatment outcome of mucormycosis patients in our hospital. Materials and methods: The study was carried out over a period of 4 years from October 2015 to October 2019. This is a retrospective observational chart review of patients diagnosed with proven and probable mucormycosis. Information on demography, clinical features, risk factors, laboratory and radiological findings, treatment (including medical and surgical treatment), and outcome was extracted from the records. Primary outcome at 42 days was determined. Results: Thirty-eight patients were diagnosed with mucormycosis based on microbiological and/or histopathological examination (HPE) of the clinical samples. Most commonly affected age-group was between 41 years and 60 years. More number of cases were reported during the months of post rainy season (September to December). A large number of patients (77%) presented with uncontrolled diabetes mellitus. Rhino-orbito-cerebral mucormycosis was the most common presentation followed by cutaneous infection. Antifungal treatment was started in around 80% of the cases. Twenty patients were managed by combined medical and surgical intervention. Eight patients died while the outcome of nine was unknown, as they left the hospital against medical advice and could not be followed up. Conclusion: Mucormycosis, an insidious killer, should be an important differential diagnosis in progressive soft tissue infections and deep organ infection.

  1. Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D’Souza O. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol 2003;51(3):231–236.
  2. Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006;44(4):335–342. DOI: 10.1080/13693780500464930.
  3. Chakrabarti A, Chatterjee SS, Das A, Panda N, Shivaprakash MR, Kaur A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J 2009;85(1009):573–581. DOI: 10.1136/pgmj.2008.076463.
  4. Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, Baghela A, Klaassen H, Meis JF. Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern. J Clin Microbiol 2010;48(12):4580–4585. DOI: 10.1128/JCM.01420-10.
  5. Ingram CW, Sennesh J, Cooper JN, Perfect JR. Disseminated zygomycosis: report of four cases and review. Rev Infect Dis 1989;11(5):741–754. DOI: 10.1093/clinids/11.5.741.
  6. Yu J, Li RY. Primary renal zygomycosis due to Rhizopus oryzae. Med Mycol 2006;44(5):461–466. DOI: 10.1080/13693780500338951.
  7. Gupta KL, Khullar DK, Behera D, Radotra BD, Sakhuja V. Pulmonary mucormycosis presenting as fatal massive haemoptysis in a renal transplant recipient. Nephrol Dial Transplant 1998;13(12):3258–3260. DOI: 10.1093/ndt/13.12.3258.
  8. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011;52(9):1144–1155. DOI: 10.1093/cid/cir122.
  9. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, Walsh TJ. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis 2012;54(Suppl 1):S67–S72. DOI: 10.1093/cid/cir884.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.